BMRN Biomarin Pharmaceutical Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: BMRN
  4. Earnings
Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 40

EPS in 2026 (TTM): -$0.09

Last Report Period Date: Sep 30, 2026

As of November 2026, according to Biomarin Pharmaceutical's latest financial report, the company's current EPS (TTM) is -$0.09. Biomarin Pharmaceutical's EPS for 2025 came in at $1.82, marking a decrease from $2.25 in 2024. Biomarin Pharmaceutical's earnings per share for the quarterly report ending on Sep 30, 2026 was -$0.63.

BMRN earnings history

Historical annual and quarterly earnings per share (EPS) data for Biomarin Pharmaceutical
EPS (TTM)
-$0.09
EPS Growth YoY (Quarterly)
-293.8%
EPS (Quarterly)
-$0.63
EPS Growth (Quarterly)
-373.9%

The annual EPS in 2025 was $1.82, a decrease of 19.1% from $2.25 in 2024. The quarterly EPS for the period ending Sep 30, 2026, was -$0.63, marking a 293.8% decrease from the same quarter last year. BMRN's TTM EPS stands at -$0.09 as of September 2026. Biomarin Pharmaceutical's EPS for 2024 stood at $2.25, a 152.8% increase from 2023.

BMRN EPS vs price chart

BMRN EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-293.8%
EPS growth YoY
-19.1%
EPS growth 3Y avg
33.8%
EPS growth 5Y avg
-17.4%

Biomarin Pharmaceutical has recorded a decrease in EPS of 293.8% over the last 12 months (YoY, quarterly). For the last three years, BMRN recorded an average annual EPS growth rate of 33.8%. Biomarin Pharmaceutical had an average annual EPS growth rate of -17.4% over the last 5 years.

BMRN Earnings Waterfall

Breakdown of revenue, profit and net income for Biomarin Pharmaceutical

BMRN Earnings vs Peers

What are the earnings of BMRN compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
RARE Ultragenyx Pharmaceutical Inc N/A 7.3% N/A N/A
BMRN Biomarin Pharmaceutical Inc N/A -19.1% 33.8% -17.4%

All data is based on quarterly TTM periods, unless otherwise specified.